Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to […]
StockNews.com assumed coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) in a report released on Thursday morning. The firm issued a strong-buy rating on the stock. Several other equities research analysts have also recently commented on NBIX. Piper Sandler dropped their target price on Neurocrine Biosciences from $103.00 to $95.00 and set a […]
First Trust Advisors LP trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 11.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 673,718 shares of the company’s stock after selling 91,049 shares during the quarter. First Trust Advisors […]
Motley Fool Asset Management LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 1,721 shares of the company’s stock, valued at approximately $206,000. A number of other hedge funds also recently made changes […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price cut by Barclays from $131.00 to $125.00 in a research note issued to investors on Thursday, The Fly reports. Several other research analysts have also recently issued reports on NBIX. StockNews.com initiated coverage on Neurocrine Biosciences in a report on Thursday, March 16th. They issued […]